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Introduction
The activity of the proteasome inhibitor bortezomib as a
single agent in relapsed and/or refractory multiple myeloma
(MM) has been established in the phase III APEX study1,2 and
in the phase III DOXIL-MMY-3001 study.3 Overall response
rates (ORR) with single-agent bortezomib in patients with
MM who had received 1-3 prior lines of therapy were 41-
43%, including 2-9% complete responses (CR), the median
time-to-progression (TTP) was 6.2-6.5 months, and the medi-
an overall survival (OS) was 29.8 months.1-3 Multiple phase II
and phase III studies have also demonstrated the activity of
bortezomib with or without dexamethasone in the setting of
relapsed and/or refractory MM.4-11 Results from several of
these studies have suggested that adding dexamethasone to
bortezomib can improve response rates in patients with sub-
optimal response to bortezomib alone.4-6,8,9 Bortezomib in com-
bination with dexamethasone is widely used in routine clinical
practice in the relapsed setting, as noted in the 2013 European
Society for Medical Oncology Clinical Practice Guidelines.12
The combination of bortezomib and dexamethasone is also
listed among the preferred regimens for salvage therapy in the
US National Comprehensive Cancer Network Clinical
Practice Guidelines for MM.13 However, phase II data report-
ing on combination treatment with bortezomib-dexametha-
sone from first relapse in MM have only recently become
available,14,15 and prospective, randomized comparative data
for bortezomib-dexamethasone versus single-agent borte-
zomib in relapsed and/or refractory MM are lacking. 
In the absence of such data, we adopted an alternative
approach for evaluating the benefit of adding dexamethasone
to bortezomib from first relapse in MM. Using patient-level
data from a phase II study of bortezomib-dexamethasone,14
and from the single-agent bortezomib arms of two phase III
studies,1,3 propensity score-matched pairs of patients were
identified for a retrospective analysis of the efficacy and safe-
ty of second-line treatment with bortezomib-dexamethasone
versus single-agent bortezomib. The matched-pair methodol-
ogy was used to control for differences in base-line character-
istics and to allow for meaningful cross-study comparisons. 
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Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data
versus single-agent bortezomib are lacking. This retrospective analysis compared second-line treatment with borte-
zomib-dexamethasone and bortezomib using 109 propensity score-matched pairs of patients treated in three clin-
ical trials: MMY-2045, APEX, and DOXIL-MMY-3001. Propensity scores were estimated using logistic regression
analyses incorporating 13 clinical variables related to drug exposure or clinical outcome. Patients received intra-
venous bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11, in 21-day cycles, alone or with oral dexamethasone 20 mg
on the days of/after bortezomib dosing. Median bortezomib cumulative dose (27.02 and 28.60 mg/m2) and treat-
ment duration (19.6 and 17.6 weeks) were similar with bortezomib-dexamethasone and bortezomib, respectively.
The overall response rate was higher (75% vs. 41%; odds ratio=3.467; P<0.001), and median time-to-progression
(13.6 vs. 7.0 months; hazard ratio [HR]=0.394; P=0.003) and progression-free survival (11.9 vs. 6.4 months;
HR=0.595; P=0.051) were longer with bortezomib-dexamethasone versus bortezomib, respectively. Rates of any-
grade adverse events, most common grade 3 or higher adverse events, and discontinuations due to adverse events
appeared similar between the groups. Two patients per group died of treatment-related adverse events. These data
indicate the potential benefit of bortezomib-dexamethasone compared with single-agent bortezomib at first
relapse in myeloma. The MMY-2045, APEX, and DOXIL-MMY-3001 clinical trials were registered at, respectively,
clinicaltrials.gov identifier: 00908232, 00048230, and 00103506.
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Figure 1. Kaplan-Meier analysis of (A)
time-to-progression (TTP), (B) progression-
free survival (PFS), and (C) overall survival
(OS) among patients in the matched-pairs
analysis treated with bortezomib-dexam-
ethasone and single-agent bortezomib.
*Log rank test stratified by matched-pair.
†Reference start date is the date of ran-
domization for randomized studies; other-
wise, the date of first dose received is
used. CI: confidence interval; HR: hazard
ratio.
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Methods
Patients, treatment, and assessments
Patient-level data from three industry-sponsored studies of
bortezomib and bortezomib-dexamethasone in relapsed and/or
refractory MM were used. Data were included from the non-ran-
domized cohort of patients treated with bortezomib-dexametha-
sone in the phase II MMY-2045 study (clinicaltrials.gov identifier:
00908232)14 and from patients randomized to single-agent borte-
zomib in the phase III APEX study of bortezomib versus high-dose
dexamethasone (clinicaltrials.gov identifier: 00048230)1 and phase III
DOXIL-MMY-3001 study of bortezomib plus liposomal doxoru-
bicin versus bortezomib alone (clinicaltrials.gov identifier: 00103506),3
the latter representing all the patient-level data on single-agent
bortezomib from randomized studies accessible to the sponsor.
Independent ethics committees/institutional review boards
approved the trials, which were conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guidelines. All
patients provided written informed consent. 
Except for 2 patients, all patients in the MMY-2045 non-ran-
domized cohort had received one prior line of therapy. Therefore,
for this analysis, involving the generation of matched pairs of
patients who had been treated with bortezomib-dexamethasone
and single-agent bortezomib, only patients with one prior line in
MMY-2045, APEX, and DOXIL-MMY-3001 were considered.
Thus, 142 patients from MMY-2045 and 242 patients from APEX
and DOXIL-MMY-3001 who had received one prior line of thera-
py were used for identification of matched pairs. All patients were
bortezomib-naïve.
Responses were assessed by International Myeloma Working
Group uniform criteria16 in MMY-2045 and European Group for
Blood and Marrow Transplantation criteria17 in APEX and DOXIL-
MMY-3001. Adverse events (AEs) were graded according to either
the National Cancer Institute (NCI) Common Toxicity Criteria
Version 2.0 or the NCI Common Terminology Criteria for Adverse
Events (CTCAE) Version 3.0. 
Matched-pairs analysis
For identification of variables to be included in a propensity
score model for the matched-pairs analysis, a systematic approach
was used following published guidelines.18-20 All base-line param-
eters consistently collected across the three studies were identi-
fied. These parameters were then categorized as being related to
study drug exposure, related to clinical outcome, or not related to
either, based on the current literature.21-30 Our initial comprehen-
sive approach for the matched-pairs analysis was to include all
identified variables, of which 13 were identified as being either
exposure- or outcome-related: age; body surface area; Eastern
Cooperative Oncology Group (ECOG) score; type of myeloma;
percent of plasma cells in the bone marrow; presence of
extramedullary plasmacytomas; prior stem cell transplantation;
prior exposure to immunomodulatory drugs (IMiDs); prior expo-
sure to dexamethasone; hemoglobin level; platelet count; creati-
nine clearance; and albumin level. Details of the propensity score
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Table 1. Base-line characteristics of patients in the 109 matched pairs
identified by propensity score matching.
Characteristic                                         Bortezomib-         Single-agent
                                                            dexamethasone       bortezomib
                                                                  (n=109)                (n=109)
Median age, years (range)                              62 (42-86)               64 (38-84)
Age ≥65 years, n (%)                                        54 (50)                     53 (49)
Median body surface area, m2 (range)      1.86 (1.4-2.4)          1.90 (1.4-2.7)
ECOG performance status, n (%)*                                                            
0                                                                             26 (24)                     25 (23)
1                                                                             71 (65)                     73 (67)
≥ 2                                                                         12 (11)                       4 (4)
IgA myeloma, n (%)†                                            28 (26)                     27 (25)
Presence of extramedullary                                4 (4)                         9 (8)
plasmacytomas, n (%)‡                                              
% Plasma cells in bone marrow, n (%)§                                                   
≤ 30%                                                                     52 (48)                     51 (47)
> 30%                                                                    46 (42)                     49 (45)
Prior stem cell transplant, n (%)                      44 (40)                     51 (47)
Prior immunomodulatory drugs, n (%)           45 (41)                     38 (35)
Prior dexamethasone, n (%)                             76 (70)                     80 (73)
Median hemoglobin, g/dL (range)             11.2 (7.2-16.4)        11.1 (7.9-15.6)
Median platelets, ×109/L (range)                198 (50-456)           199 (24-523)
Creatinine clearance <50 mL/min, n (%)‡      22 (20)                     21 (19)
Median albumin, g/dL (range)                      4.0 (2.0-5.1)            3.9 (2.1-5.5)
*Missing for 7 (6%) single-agent bortezomib patients. †Missing for 7 (6%) bortezomib-
dexamethasone patients. ‡Missing for one (1%) bortezomib-dexamethasone patient.
§Missing for 11 (10%) bortezomib-dexamethasone patients and 9 (8%) single-agent
bortezomib patients. ECOG: Eastern Cooperative Oncology Group; Ig: immunoglobulin.
Table 2. Response rates with bortezomib-dexamethasone and single-
agent bortezomib in the matched-pairs analysis.
Response, Bortezomib- Single-agent OR P
n (%) dexamethasone bortezomib (95% CI)
(n=109) (n=109)
ORR (CR + PR)* 82 (75.2) 45 (41.3) 3.467 <0.001†
(1.952-6.157)
CR 11 (10.1) 9 (8.3) – –
PR 71 (65.1) 36 (33.0) – –
Stable disease 9 (8.3) 51 (46.8) – –
Progressive disease 3 (2.8) 8 (7.3) – –
Not evaluable 15 (13.8) 5 (4.6) – –
*Assessed according to International Myeloma Working Group uniform criteria for the
bortezomib-dexamethasone group and according to European Group for Blood and
Marrow Transplantation criteria for the single-agent bortezomib group. †Cochran-
Mantel-Haenszel χ2 test, stratified by matched pair.  CI: confidence interval; CR: com-
plete response; OR: odds ratio; ORR: overall response rate; PR: partial response.
Table 3. Efficacy results for the bortezomib-dexamethasone versus
single-agent bortezomib matched-pairs analysis and the two sensitiv-
ity analyses.
End point Matched-pairs Covariate-adjusted Propensity
analysis regression score-weighted
(n=109 pairs) (n=384) regression
(n=384)
ORR 3.467 3.774 3.628
OR (95% CI) (1.952-6.157) (2.174-6.551) (2.107-6.245)
TTP 0.394 0.387 0.353
HR (95% CI) (0.207-0.748) (0.271-0.554) (0.242-0.516)
PFS 0.595 0.497 0.433
HR (95% CI) (0.351-1.008) (0.357-0.692) (0.305-0.613)
OS 0.958 1.067 0.903
HR (95% CI) (0.541-1.698) (0.672-1.694) (0.571-1.429)
CI: confidence interval; HR: hazard ratio; OR: odds ratio; ORR: overall response rate; OS:
overall survival; PFS: progression-free survival; TTP: time-to-progression.
model for identifying matched patient pairs are provided in the
Online Supplementary Appendix.
A second, confirmatory matched-pairs analysis was conducted
using the same methodology, but in which the propensity score
model was estimated using only 8 of the 13 identified variables –
those mainly associated with clinical outcome (i.e. of prognostic
importance in myeloma): age; ECOG score; type of myeloma;
percent of plasma cells in the bone marrow; prior exposure to dex-
amethasone; hemoglobin level; creatinine clearance; and albumin
level.
Statistical analysis of response rates and time-to-event out-
comes in the treatment groups, and details of the sensitivity analy-
ses performed, are provided in the Online Supplementary Appendix.
Results
Matched pairs of patients
From the 384 patients included in this analysis, a total of
109 matched pairs of patients (n=218) treated with borte-
zomib-dexamethasone and single-agent bortezomib were
identified by the first propensity score matching model.
The base-line characteristics of these matched pairs of
patients are summarized in Table 1. As expected, the
groups were well balanced with respect to these variables,
which were used in the propensity score matching model.
The median time since initial diagnosis was 2.7 years
(range 0.2-11.2 years) in the bortezomib-dexamethasone
group and 2.0 years (range 0.4-24.9 years) in the single-
agent bortezomib group.
Exposure to bortezomib was similar between groups.
Median duration of treatment was 19.6 versus 17.6 weeks
in the bortezomib-dexamethasone and single-agent borte-
zomib groups, respectively. The respective median cumu-
lative doses of bortezomib were 27.02 mg/m2 (range 1.3-
41.7 mg/m2) and 28.60 mg/m2 (range 2.4-59.1 mg/m2). In
the bortezomib-dexamethasone group, patients received a
median cumulative dose of dexamethasone of 880 mg
(range 20-1280 mg).
Efficacy
The ORR was significantly higher with bortezomib-
dexamethasone versus single-agent bortezomib, at 75%
versus 41% (odds ratio [OR] = 3.467; P<0.001) (Table 2).
The CR rate appeared similar at 10% versus 8%. 
Time-to-progression was significantly longer, and there
was a trend to longer progression-free survival (PFS), with
bortezomib-dexamethasone versus single-agent borte-
zomib (Figure 1A and B). With 47% and 49% of patients
having progressed, respectively, the median TTP was 13.6
versus 7.0 months with bortezomib-dexamethasone versus
single-agent bortezomib, with a hazard ratio (HR) of 0.394
(P=0.003). With 57% and 53% of patients having pro-
gressed or died, respectively, median PFS was 11.9 versus
6.4 months, with an HR of 0.595 (P=0.051) in favor of
bortezomib-dexamethasone. In the additional analysis of
PFS with stratification by propensity score quintile instead
of by matched pair, the HR was 0.539 (95% confidence
interval [CI]: 0.365-0.796; P=0.002).
After a median follow up of 26.1 months and 18.4
months, respectively, 30% and 26% of patients in the
bortezomib-dexamethasone and single-agent bortezomib
groups had died. The median OS was not reached in
either group and the HR was 0.958. In the bortezomib-
dexamethasone and single-agent bortezomib groups,
respectively, 1- and 2-year OS rates were 78.7% and
68.4%, and 86.4% and 62.2% (Figure 1C). In an additional
time-dependent analysis of OS, adjusting for onset of sub-
sequent therapy, there was no difference in OS between
the bortezomib-dexamethasone and single-agent borte-
zomib groups (HR 1.012; 95%CI: 0.547-1.873).
Sensitivity analyses of ORR and the time-to-event end
points, using covariate-adjusted and propensity score-
weighted regression analyses of all 384 patients, showed
findings consistent with those from the matched-pairs
analysis (Table 3). ORs for ORR were 3.774 and 3.628,
HRs for PFS were 0.497 and 0.433, HRs for TTP were
0.387 and 0.353, and HRs for OS were 1.067 and 0.903 in
these two analyses, respectively. In addition, efficacy
results from the second, confirmatory matched-pairs
analysis (n=127 pairs) employing only the eight variables
associated with clinical outcome in the propensity score
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Table 4. Efficacy results for bortezomib-dexamethasone versus single-
agent bortezomib in a confirmatory matched-pairs analysis (n=127).
Bortezomib- Single-agent
dexamethasone bortezomib
(n=127) (n=127)
ORR, n (%) 93 (73.2) 57 (44.9)
OR (95% CI) 3.769 (2.045-6.947)*
Median TTP, months (95% CI) 12.9 (9.5-15.7) 6.4 (5.7-7.2)
HR (95% CI) 0.385 (0.212-0.698)†
Median PFS, months (95% CI) 10.7 (7.4-15.3) 6.2 (5.0-7.0)
HR (95% CI) 0.511 (0.309-0.845)‡
OS rate, % (95% CI)
1-year 79.3 (70.9-85.5) 80.4 (71.9-86.5)
2-year 69.6 (60.2-77.3) 54.7 (42.3-65.4)
*P<0.001 by Cochran-Mantel-Haenszel χ2 test, stratified by matched pair. †P=0.001 
by log rank test, stratified by matched pair. ‡P=0.008 by log rank test, stratified by
matched pair. CI: confidence interval; HR: hazard ratio; OR: odds ratio; ORR: overall
response rate; OS: overall survival;  PFS: progression-free survival; 
TTP: time-to- progression.
Table 5. Summary of safety data for bortezomib-dexamethasone and
single-agent bortezomib in the matched-pairs analysis.
Treatment-emergent                        Bortezomib-               Single-agent
AEs, n (%)                                     dexamethasone              bortezomib
                                                          (n=109)                      (n=109)
Any AE                                                           104 (95)                           108 (99)
Any grade ≥3 AE                                          72 (66)                             82 (75)
Common grade ≥3 AEs:                                                                              
Thrombocytopenia                                  23 (21)                             27 (25)
Infections                                                  19 (17)                             17 (16)
Peripheral neuropathy*                          20 (18)                             14 (13)
Neutropenia                                                4 (4)                               18 (17)
Any grade ≥4 AE                                          19 (17)                             20 (18)
Any serious AE                                             40 (37)                             50 (46)
Discontinuations due to AEs                    30 (28)                             34 (31)
On-study deaths due to AEs                       9 (8)                                 3 (3)
Drug-related AEs                                       2 (2)                                 2 (2)
*Rates for peripheral neuropathy include multiple preferred terms in addition to the
high-level term of peripheral neuropathy not elsewhere classified (neuropathy peripher-
al, peripheral sensory neuropathy, peripheral sensorimotor neuropathy, peripheral motor
neuropathy), plus polyneuropathy, neuralgia, paresthesia, hypoesthesia, hyperesthesia,
dysesthesia, and burning sensation); additional terms were included to overcome differ-
ences between studies in AE coding. AE: adverse event.  
matching methodology (Table 4) were consistent with the
findings of the 13-variable matched-pairs analysis. 
Safety
The safety profiles of bortezomib-dexamethasone and
single-agent bortezomib in the matched-pairs analysis are
summarized in Table 5. Overall rates of any-grade AEs,
grade 4 or higher AEs, and discontinuations due to AEs
appeared similar between the groups. There were numeri-
cally lower rates of grade 3 or higher AEs and serious AEs
in the bortezomib-dexamethasone group. Common grade
3 or higher AEs, with rates for bortezomib-dexamethasone
versus single-agent bortezomib, were thrombocytopenia
(21% vs. 25%), infections (17% vs. 16%), peripheral neu-
ropathy (18% vs. 13%), and neutropenia (4% vs. 17%). 
There was a numerically higher rate of on-treatment
deaths due to AEs in the bortezomib-dexamethasone
group (8%) compared with the single-agent bortezomib
group (3%). Of the 9 patients who died on-study due to
AEs in the bortezomib-dexamethasone group, median age
was 72 years and 7 (78%) were aged 65 years or over
(whereas the median age was 62 years and 50% were
aged 65 years or over in the overall population in the
bortezomib-dexamethasone group), 7 (78%) had creati-
nine clearance of 60 mL/min (compared with 31% in the
overall population), and 5 (56%) had serum albumin 
3.5 g/dL (compared with 21% in the overall population);
other base-line characteristics were similar.
Adverse events resulting in on-study deaths that were
not considered related to treatment in the bortezomib-
dexamethasone group included: septic shock in a patient
with a high disease burden and a history of thrombocy-
topenia and anemia; aortic aneurysm in a patient aged 70
years with base-line serum creatinine 3.1 mg/dL; myocar-
dial infarction in a patient with a history of hypertension;
small intestinal obstruction in a patient with a high disease
burden, extensive lymph node enlargement, and amyloi-
dosis of the duodenum; cardiorespiratory arrest that was a
post-operative (bone fracture) complication in a patient
with a history of diabetes mellitus, hypertension, and
myocardial infarction; acute respiratory failure; and viral
infection in a patient with a history of chronic obstructive
pulmonary disease, chronic urinary tract infection, sick
sinus syndrome, and pacemaker implantation. In the sin-
gle-agent bortezomib group, one on-study death not con-
sidered related to treatment occurred; this was due to a
road traffic accident.
Two patients (2%) in each group died due to treatment-
related AEs. In the bortezomib-dexamethasone group,
these were sepsis in one patient with a history of divertic-
ulitis, anterior resection of the large bowel, and a fistula
repair of the bowel and bladder (considered to be possibly
related to dexamethasone), and oliguria, hypotension, and
acute respiratory distress syndrome, all considered to be
possibly related to bortezomib, in one patient with a histo-
ry of arterial hypertension, anemia, diabetes mellitus, and
decreased glomerular filtration rate. In the single-agent
bortezomib group, these were both AEs of pneumonia. 
Discussion
This matched-pairs analysis comparing bortezomib-
dexamethasone with single-agent bortezomib as second-
line treatment for MM showed that the ORR was signifi-
cantly improved and TTP and PFS were prolonged with
the addition of dexamethasone to bortezomib. Our results
also appear to suggest that the addition of dexametha-
sone, per the dose and schedule received by patients in the
MMY-2045 study, to bortezomib is not associated with
increased toxicity. Together, these data indicate the poten-
tial benefit of using bortezomib-dexamethasone from first
relapse in MM, compared with single-agent bortezomib.
There was no difference in OS between the two groups.
OS did not appear to be influenced by the receipt of sub-
sequent salvage therapy; however, a comprehensive
analysis of time to next therapy and the nature of subse-
quent therapy received by patients after second-line borte-
zomib-based treatment was not possible due to inconsis-
tencies in the methods of data collection between the
APEX, DOXIL-MMY-3001, and MMY-2045 studies. As
there was a gap of 5-6 years between the conduct of the
APEX/DOXIL-MMY-3001 studies and the MMY-2045
study, it is possible that the front-line and subsequent
treatment options available to patients in these different
trials may have contributed to a lack of difference in OS
between the two groups in the present analysis; however,
subsequent therapy data were not consistently collected in
MMY-2045 in order to test this hypothesis. Alternatively,
relapse/progression due to the outgrowth of corticos-
teroid-insensitive MM clones, which may occur in the
presence or absence of prior steroid therapy, might have
contributed to the observed lack of difference in OS
between bortezomib-dexamethasone and single-agent
bortezomib in this study. 
The efficacy and safety findings of this matched-pairs
analysis are supported by previously published data on
bortezomib ± dexamethasone from prospective clinical
trials,4,5,7-11,14,15,31 as well as by data from retrospective,32-34
observational,35,36 and compassionate use37 studies in
relapsed and/or refractory MM, and by data from previous
prospective clinical trials of single-agent bortezomib in
this setting.1-3,38 The improved ORR and prolonged TTP
and PFS observed in patients treated with bortezomib-
dexamethasone may be due, in part, to synergism
between the two drugs, supported by pre-clinical data
indicating that bortezomib enhances the anti-myeloma
effects of dexamethasone,39 or to an additive rather than
synergistic effect of dexamethasone,40 particularly in first
relapse when patients may remain sensitive to glucocorti-
coids. Our data reflect previous clinical experience demon-
strating the activity of the combination therapy and the
additional activity seen when dexamethasone has been
added due to suboptimal response to single-agent borte-
zomib.4-6,8,9 The findings of this matched-pairs analysis are
also supported by the results of the BoMeR study, which
compared prospective data on bortezomib-dexametha-
sone treatment with data from patients treated with sin-
gle-agent bortezomib in APEX.15 However, it is worthy of
note that patients included in the BoMeR study addition-
ally received maintenance therapy with bortezomib-dex-
amethasone; therefore, long-term outcomes data are not
comparable with the present analysis. It should be noted
that the 109 matched pairs of patients contributing to the
data in this analysis only represent a subset of the overall
study populations receiving bortezomib-dexamethasone
in MMY-2045 and single-agent bortezomib in APEX and
DOXIL-MMY-3001, which may explain the differences
between the ORR, PFS, TTP, and OS data in this analysis
and in the overall study results.1-3,14
The rationale for performing a matched-pairs analysis
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to evaluate the benefit/risk profile of bortezomib-dexam-
ethasone in comparison with bortezomib monotherapy
was that this methodology can reduce selection bias due
to differences in base-line prognostic factors and improve
comparability of the patient populations between treat-
ment groups, leading to reliable conclusions for cross-
study comparisons. Further to the primary matched-pairs
analysis, the additional data analyses and sensitivity
analyses conducted were supportive of the primary find-
ings. The alternative analysis of PFS, which employed
stratification by propensity score quintile instead of by
matched pair, resulted in improved power for the com-
parison between groups and, consequently, a narrower
95% CI. Extending the primary findings, this analysis
demonstrated a statistically significant improvement in
PFS with bortezomib-dexamethasone versus single-agent
bortezomib. The findings of the sensitivity analyses,
using alternative methodologies for comparing ORR and
time-to-event end points between groups, and incorpo-
rating all 384 patients who received bortezomib-dexam-
ethasone or single-agent bortezomib as second-line ther-
apy, appeared consistent or highly consistent with the
findings of the primary matched-pairs analysis, support-
ing the validity of these findings. In addition, the second,
confirmatory matched-pairs analysis, using only eight
variables primarily associated with treatment outcome,
also provided consistent findings, further supporting
these results. The results of this confirmatory matched-
pairs analysis have led to regulatory approval in the
European Union of the use of bortezomib in combination
with dexamethasone for adult patients with progressive
MM who have received at least one prior therapy and
who have already undergone or who are unsuitable for
hematopoietic stem cell transplantation.41 They also pro-
vide a solid justification to consider bortezomib-dexam-
ethasone as the backbone regimen upon which more
intensive rationally informed triplet therapies [such as
bortezomib-thalidomide-dexamethasone (VTD),
lenalidomide-bortezomib-dexamethasone (RVD), and
bortezomib-cyclophosphamide-dexamethasone (VCD)]
have been built.42,43
This matched-pairs analysis had some limitations. An
inherent limitation was that this was not a prospective,
randomized, controlled comparison between bortezomib-
dexamethasone and single-agent bortezomib, the gold-
standard method for establishing comparative data. In
addition, although the matched-pairs analysis was thor-
ough and included 13 variables associated with treatment
duration and outcomes, it was nevertheless limited by the
information that was collected consistently across all three
clinical studies. Some relevant variables, such as fluores-
cence in situ hybridization/cytogenetics data, response to
prior therapy, and base-line β2-microglobulin level, were
not collected consistently and, therefore, could not be
included in this matching exercise; thus, we cannot
exclude the possibility that there was an imbalance
between the two groups for certain prognostic factors.
Furthermore, the MMY-2045 study was conducted more
recently than the APEX and DOXIL-MMY-3001 studies,
and management of bortezomib may thus have improved
due to increased experience with this agent, contributing
towards lower peripheral neuropathy and serious AE rates
in the bortezomib-dexamethasone group. However,
bortezomib exposure and treatment duration appeared
similar between the bortezomib-dexamethasone and sin-
gle-agent bortezomib groups, and thus did not appear to
be associated with the efficacy differences. 
In conclusion, bortezomib-dexamethasone appears an
active and generally well tolerated treatment option for
second-line therapy in MM. In the absence of randomized
study data, the findings of these thorough matched-pairs
analyses indicate that, in this setting, the doublet offers
greater efficacy in terms of response and delayed progres-
sion compared with single-agent bortezomib, without an
appreciable increase in the toxicity profile. 
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